1. Home
  2. HXL vs IBRX Comparison

HXL vs IBRX Comparison

Compare HXL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$96.87

Market Cap

7.4B

Sector

Industrials

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.69

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXL
IBRX
Founded
1946
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
7.2B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
HXL
IBRX
Price
$96.87
$7.69
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$88.30
$12.57
AVG Volume (30 Days)
879.8K
11.5M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
0.80%
N/A
EPS Growth
N/A
38.71
EPS
N/A
N/A
Revenue
$1,893,900,000.00
$113,288,000.00
Revenue This Year
$10.09
$88.59
Revenue Next Year
$12.33
$131.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
668.31
52 Week Low
$56.20
$1.95
52 Week High
$101.51
$12.43

Technical Indicators

Market Signals
Indicator
HXL
IBRX
Relative Strength Index (RSI) 57.69 55.17
Support Level $81.10 $6.69
Resistance Level $97.69 $8.54
Average True Range (ATR) 3.24 0.44
MACD 0.14 0.08
Stochastic Oscillator 65.65 78.91

Price Performance

Historical Comparison
HXL
IBRX

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: